Application of sandostatin in malignant bowel obstruction.
- Author:
Jian LI
1
;
Mao-lin JING
;
Lin SHEN
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Female; Humans; Intestinal Obstruction; drug therapy; etiology; Male; Middle Aged; Octreotide; therapeutic use; Prognosis; Retrospective Studies; Stomach Neoplasms; complications; drug therapy; Treatment Outcome
- From: Chinese Journal of Gastrointestinal Surgery 2007;10(5):479-481
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the effects of sandostatin in the treatment of malignant bowel obstruction(MBO).
METHODSThe data of 51 patients with MBO from Aug. 1996 to June. 2004 were analyzed retrospectively. All the patients were divided into two groups: routine treatment group (n=19) and sandostatin combined with routine treatment group (n=32). Symptoms, gastrointestinal secretions, nasogastric tube(NGT) removing and effects of sandostatin on different obstructive location were observed.
RESULTSThe symptom improvement in sandostatin group was 20/32 (63.1%) which was significantly higher than 4/19 (21.1%) in routine treatment group (P< 0.01). The average G-I secretion was (398 +/- 152) ml and (834 +/- 306) ml in sandostatin and traditional group respectively and the difference was significant (P< 0.05). No severe side and toxic effects were found during therapy.
CONCLUSIONSandostatin can effectively relieve clinical symptoms and improve life quality in the bowel obstruction cases with advanced cancers.
